Medical Design and Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech

Potential Mechanism of Action Identified for the Treatment of Major Depression With Trigeminal Nerve Stimulation (TNS) – The USB Port to the Brainâ„¢

July 5, 2011 By Bio-Medicine.Org

LOS ANGELES, July 5, 2011 /PRNewswire/ — NeuroSigma, a Los
Angeles-based neuromodulation company, today announced that a
recent Phase I clinical trial revealed that external Trigeminal
Nerve Stimulation (eTNS™) increased regional cerebral blood
flow in brain regions associated with depression and mood
regulation.  eTNS™ was shown to be a potential therapy
for depression, with significant reductions in depression severity
during the 8-week adjunctive treatment period.  These
encouraging results have led to a Phase II double-blind trial with
expected completion later this year.

(Photo: http://photos.prnewswire.com/prnh/20110705/NY29679
)

eTNS™ and Depression

Trigeminal Nerve Stimulation (TNS) is a promising new therapy
for the treatment of major depression without the typical side
effects of antidepressants.  TNS was invented by researchers
at UCLA and is exclusively licensed to NeuroSigma.  

In June of last year, UCLA investigators reported preliminary
results from the first five patients of the open-label Phase I TNS
feasibility trial, noting a 70% reduction in symptom severity over
the 8-week acute phase of treatment, resulting in an 80% remission
rate. (
http://newsroom.ucla.edu/portal/ucla/non-invasive-therapy-significantly-169741.aspx
).
 

Last month, at the New Clinical Drug Evaluation Unit (NDCEU)
51st Annual Meeting in Boca Raton, Florida, Ian Cook, M.D., the
Joanne and George Miller Family Chair in Depression Research at the
Semel Institute at UCLA, and a medical advisor to NeuroSigma,
presented additional data from four new subjects enrolled in this
Phase I trial, which included functional neuroimaging PET data.
 Cook noted that “with just brief exposure to eTNS™,
significant increases in regional cer

‘/>”/>

SOURCE

Related Articles Read More >

Dexcom One
How Dexcom’s portfolio goes beyond highly-anticipated next-gen G7
A portrait of Stryker executive Siddarth Satish
How Stryker includes users for product design in the digital age
A Medtronic HVAD pump opened up to show the inner workings
Medtronic investigates HVAD pump welds after patient deaths
Galien Foundation 2022 nominees
18 of the world’s most innovative medical technologies

DeviceTalks Weekly.

May 13, 2022
Our Pre-Post-DeviceTalks Boston episode, also MedtronicTalks replay with Gastro CMO Austin Chiang
See More >

MDO Digital Edition

Digital Edition

Subscribe to Medical Design & Outsourcing. Bookmark, share and interact with the leading medical design engineering magazine today.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
DeviceTalks

DeviceTalks is a conversation among medical technology leaders. It's events, podcasts, webinars and one-on-one exchanges of ideas & insights.

DeviceTalks

New MedTech Resource

Medical Tubing

Enewsletter Subscriptions

Enewsletter Subscriptions

MassDevice

Mass Device

The Medical Device Business Journal. MassDevice is the leading medical device news business journal telling the stories of the devices that save lives.

Visit Website
MDO ad
Medical Design and Outsourcing
  • MassDevice
  • DeviceTalks
  • MedTech 100 Index
  • Medical Tubing + Extrusion
  • Drug Delivery Business News
  • Drug Discovery & Development
  • Pharmaceutical Processing World
  • R&D World
  • About Us/Contact
  • Advertise With Us
  • Subscribe to Print Magazine
  • Subscribe to E-newsletter
  • Attend our Monthly Webinars
  • Listen to our Weekly Podcasts
  • Join our DeviceTalks Tuesdays Discussion

Copyright © 2022 WTWH Media, LLC. All Rights Reserved. Site Map | Privacy Policy | RSS

Search Medical Design & Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech